Stockscreener 앱 받기
62.53
1.63%
1.00
시간 외 거래:
62.53
Biomarin Pharmaceutical Inc 주식(BMRN)의 최신 뉴스
Sabry Lays Out BioMarin’s New Business Development Plan - News & Insights
Earnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospects - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - Insider Monkey
10 Under-the-Radar Stocks with Massive Upside for 2025 - Insider Monkey
Avanza Fonder AB Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Sees Large Decrease in Short Interest - MarketBeat
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Down 3%Should You Sell? - MarketBeat
BioMarin Pharmaceutical Target of Unusually High Options Trading (NASDAQ:BMRN) - MarketBeat
BioMarin stock touches 52-week low at $60.77 amid challenges - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 52-Week LowWhat's Next? - MarketBeat
BioMarin files UPC’s first pharma infringement suit in over three months - IAM
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Simply Wall St
Assenagon Asset Management S.A. Grows Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Wedmont Private Capital Makes New $430,000 Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Down 3%What's Next? - MarketBeat
UTHR: 3 Niche Biotech Stocks Redefining Innovation - StockNews.com
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
5 Biotech Stocks Worth Adding to Your Portfolio in 2025 - Yahoo Finance
Goldman Sachs maintains Buy on BioMarin shares - Investing.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.20 Consensus Target Price from Analysts - MarketBeat
BioMarin sues Ascendis Pharma over patent infringement By Investing.com - Investing.com Canada
BioMarin sues Ascendis Pharma over patent infringement - Investing.com
BioMarin Takes Legal Action Against Ascendis Over CNP Patent in European Court - StockTitan
Wall Street Analysts Predict a 45.86% Upside in BioMarin (BMRN): Here's What You Should Know - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Zacks Research Has Optimistic Outlook of BMRN Q2 Earnings - MarketBeat
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - MSN
Zacks Research Analysts Lift Earnings Estimates for BMRN - MarketBeat
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Trading 2.4% HigherStill a Buy? - MarketBeat
XBI, NBIX, GILD, BMRN: Large Outflows Detected at ETF - Nasdaq
Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical - Yahoo Finance
BMRNBioMarin Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA - PR Newswire
BioMarin CEO to Present at J.P. Morgan Healthcare Conference 2024 - StockTitan
BioMarin plans €60m expansion at Shanbally site - The Southern Star
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) - Yahoo Finance
BMRN or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI - GlobeNewswire Inc.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Down 9.4% in December - MarketBeat
Sangamo Shares Nosedive as Pfizer Drops Hemophilia Drug Pact - Wall Street Pit
Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet? - Simply Wall St
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position Trimmed by Principal Financial Group Inc. - MarketBeat
First Week of February 2025 Options Trading For BioMarin Pharmaceutical (BMRN) - Nasdaq
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock? - MSN
Stifel Financial Corp Decreases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.20 Average Price Target from Brokerages - MarketBeat
4.81%
자본화:
|
볼륨(24시간):